Dubai, United Arab Emirates: A new chapter in the UAE’s technological future begins today with the official opening of the AI ...

Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal ...

CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13th, ...

Q3 2025 Management View Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of the third quarter, NRx has made transformative progress in ...

EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) ("EnviroGold" or the "Company") is pleased to announce the publication of ...

The collaboration marks a key milestone under the Smart and Autonomous Vehicle Industries (SAVI) cluster, accelerating ...

PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...

For decades, fusion energy was often seen as a concept from science fiction—a promise that seemed forever on the horizon.

The FDA has granted full approval to Kura Oncology and Kyowa Kirin’s Komzifti (ziftomenib), marking the first FDA-approved once-daily, oral menin inhibitor for adults with relapsed or refractory (R/R) ...

HIGHLIGHTS Conference Call Information The Company will hold a conference call to discuss its financial results for the second quarter of 2025 at 8:30 a.m. ET on Friday, November 14, 2025.

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio ...

Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...